The Food and Drug Administration has approved expanded use of Dysport to treat upper- and lower-limb spasticity – including that caused by cerebral palsy – for patients as young as 2 years and older, ...

The safety and efficacy of repeat injections of botulinum toxin A (BTX-A) into the upper limb of children with spastic hemiplegic cerebral palsy (CP) who are receiving occupational therapy has not yet ...

The study used 2016-2020 information from the Pediatric Health Information System (PHIS), an administrative database that includes more than 49 children's hospitals. The authors stratified study ...

The FDA has approved the expanded use of Botox® (onabotulinumtoxinA; Allergan) for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by ...

– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity1 – – Pivotal Phase 3 study demonstrated Dysport improved spasticity ...

Doctors use a few different scales when looking at how cerebral palsy affects your body and life. It’s important to note that these scales aren’t progressive. Cerebral palsy is a motor condition that ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a label expansion for Botox to include eight new muscles and the use of ultrasound for the ...

Special needs children are seeing improved motor function thanks to therapies that force them to rely on their affected limbs, medical experts say. Several studies back up the results, while others ...

Though rare, cerebral palsy can sometimes cause hypotonic symptoms, or chronic muscle weakness. Treatments such as physical therapy or surgery can help improve mobility. Cerebral palsy is a physical ...

The FDA has approved Botox for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. The treatment was already approved for ...